JPRN-jRCTs021180030
Completed
未知
Effect of antiviral agent against cytomegalovirus corneal endothelitis - Effect of antiviral agent against cytomegalovirus corneal endothelitis
Tando Toshio0 sites10 target enrollmentStarted: March 25, 2019Last updated:
Overview
- Phase
- 未知
- Status
- Completed
- Sponsor
- Tando Toshio
- Enrollment
- 10
Overview
Brief Summary
The study started with an investigation of the therapeutic effects of antiviral drugs on cytomegalovirus corneal endotheliitis, but this study was based on off-label use of drugs.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Cytomegalovirus coreal endotheliitis established by the Japan Corneal Endotheliitis Study Group which was authorised by the Japanese Ministry of Health, Labour and Welfare
Exclusion Criteria
- •Patients which did not agree to join this clinical trial
Investigators
Similar Trials
Completed
Phase 3
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationCancerNCT00045292Fred Hutchinson Cancer Center
Recruiting
Phase 3
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: a multicenter, open-label randomized controlled clinical trialHIV/AIDSTuberculosisCytomegalovirus pneumoniaRespiratoryPaediatricsPACTR201904797961340Servicio Madrileno de Salud Fundacion para la Investigacion Biomedica Hospital Universitario 12 de Octubre624
Terminated
Phase 3
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled TrialCongenital Cytomegalovirus InfectionSensorineural Hearing LossNCT01655212Dr. Ann C.T.M. Vossen2
Completed
Phase 2
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaPneumoniaHIV/AIDSTuberculosisCytomegalovirus InfectionsNCT03915366Hospital Universitario 12 de Octubre563
Active, not recruiting
Phase 1
Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with or without antiviral therapyPatient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 1 and 2 biopsies of the inflammatory tissue and presence of a CMV infection in the inflammatory tissue objectified by a viral load greater than 5 IU / 100000 cells by qPCR.MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10058881Term: Cytomegalovirus viremiaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2019-001032-54-FRCHU de Saint Etienne120